Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abbott Laboratories
(NY:
ABT
)
112.69
+0.59 (+0.53%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abbott Laboratories
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst
March 15, 2024
Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil.
Via
Investor's Business Daily
Topics
Death
Exposures
Death
SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster
March 13, 2024
With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors.
Via
InvestorPlace
Topics
ETFs
Medtronic is a Dividend Aristocrat That Keeps Gaining
March 11, 2024
A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector
Via
MarketBeat
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
March 11, 2024
These are some of the best-performing stocks in what's arguably society's most important industry.
Via
The Motley Fool
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
March 08, 2024
Via
Benzinga
Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now?
March 07, 2024
Abbott Laboratories has been growing its dividend at a blistering pace. Is its stock a buy?
Via
The Motley Fool
Exploring ABBOTT LABORATORIES (NYSE:ABT)s quality characteristics.
March 05, 2024
Why the quality investor may take a look at ABBOTT LABORATORIES (NYSE:ABT).
Via
Chartmill
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
March 01, 2024
Via
Benzinga
Are These 5 Undervalued Stocks Ready to Break Out?
March 08, 2024
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.
Via
MarketBeat
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's
March 06, 2024
FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant...
Via
Benzinga
Exposures
Product Safety
3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates
March 06, 2024
These three dividend stocks have proved themselves to be among the best Dividend Aristocrats to buy for high-growth returns.
Via
InvestorPlace
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
March 06, 2024
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it.
Via
Investor's Business Daily
Exposures
Product Safety
Could Abbott Laboratories Stock Help You Become a Millionaire?
February 26, 2024
Abbott's earnings have soared over the past decade.
Via
The Motley Fool
Abbott Laboratories (NYSE: ABT) Records 52-Week High Friday Morning
February 23, 2024
Via
Investor Brand Network
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment
February 23, 2024
Via
Benzinga
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
March 03, 2024
There is a world of opportunities ahead for this healthcare giant.
Via
The Motley Fool
Nearing Retirement? These Stocks Are as Cautious as They Come
February 28, 2024
Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further.
Via
The Motley Fool
3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade
February 27, 2024
These stocks don't offer the highest yields, but their payouts are growing fast.
Via
The Motley Fool
3 Blue-Chip Stocks to Buy to Bolster Your Portfolio
February 26, 2024
Delve into three undervalued blue-chip stocks to buy driving growth in consumer staples, pharmaceuticals, and healthcare.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
February 26, 2024
Via
Benzinga
Peering Into Abbott Laboratories's Recent Short Interest
February 20, 2024
Via
Benzinga
Looking for Growth? 7 Hot Trends That Have Been Flying Under Investors’ Radar.
February 26, 2024
Discover 7 under-the-radar stock trends set to make waves in the stock market. Find out why savvy investors are tuning in.
Via
InvestorPlace
Recession-Proof Riches: 7 Stocks to Buy for Bulletproof Portfolio Growth
February 23, 2024
Explore recession-proof stocks thriving in Energy, Health Care, Industrials, and more, offering stability and growth amid economic turmoil.
Via
InvestorPlace
Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade
February 21, 2024
In a welcome move, Abbott Laboratories stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday.
Via
Investor's Business Daily
3 Cash Cows to Boost Your Confidence During the February Chill
February 18, 2024
The market can be a tricky place. Bet on these cash cow stocks to help restore confidence and extract steady returns.
Via
InvestorPlace
The Smartest Dividend Stocks to Buy With $400 Right Now
February 18, 2024
These stocks reward you during any market environment.
Via
The Motley Fool
Cardiology's Quantum Leap: FDA's Advisory Panel Gives Thumbs Up To Abbott's Minimally Invasive Heart Valve Repair Device
February 14, 2024
FDA panel confirms support (13-1) for Abbott Laboratories' TriClip TEER system in treating tricuspid regurgitation. Approval decision expected from FDA in 2024.
Via
Benzinga
Exposures
Product Safety
FDA Advisors Set To Discuss Abbott's TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom
February 12, 2024
FDA to review Abbott's TriClip G4 System for severe tricuspid regurgitation. Circulatory System Devices Panel meeting and insights from the briefing document.
Via
Benzinga
Exposures
Product Safety
Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How.
February 11, 2024
Abbott Labs has an impressive portfolio of nutrition drinks, and its latest addition could help it profit from a new market: people taking prescribed weight loss drugs.
Via
The Motley Fool
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
February 11, 2024
Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.